Research updates, business developments, and important news from the psychedelic therapy and wellness industry.
Follow this category for clinical, policy, and business signals that affect access to supervised psychedelic care. Start with the psilocybin therapy guide for the full protocol, then compare supervised psilocybin with ketamine therapy and the broader psilocybin vs MDMA vs ketamine treatment landscape.
Recent industry posts track 2026 therapy trends, therapy cost, and common mistakes to avoid. For treatment-fit questions, use the conditions hub.
The most important signals to watch are trial quality, real-world access, cost, and safety screening. A headline about growth is more useful when it tells you who can access care, who should avoid it, and what support happens before and after the session. For safety context, review SSRIs, lithium, and MAOI interaction guidance.
8 posts in Industry News
A 2026 Nature Communications study in psychedelic-naïve adults found measurable brain-network and white-matter changes lasting at least a month after a single 25mg psilocybin session.
From COMP360's Phase 3 milestone to Colorado's rapid scale-up and MDMA's FDA resubmission, these are the five psychedelic therapy developments worth tracking in 2026.
Legal psilocybin therapy in Oregon or Colorado costs $1,500–$3,500 per complete experience. Retreats abroad run $3,000–$8,000+. Here's exactly what drives cost, what's included, and how to reduce it.
Most problems in psilocybin therapy are preventable. Here are the seven most common mistakes — stopping SSRIs abruptly, skipping integration, choosing an unverified facilitator — and exactly what to do instead.
From sub-perceptual microdoses to high-dose sessions, dose strongly shapes outcomes. We break down the evidence by dose range and what it means for therapy and personal use.
Early studies suggest that auditory stimulation and psilocybin may each influence brain rhythms and plasticity. We look at what's known and what's speculative in the context of Alzheimer's and cognitive decline.
Researchers find significant and lasting reductions in depression symptoms after just two guided psilocybin sessions.
As legal access expands, advocates push for insurance coverage. Here's where the conversation stands in 2026.